Kornimate/medical-research-clean huggingface dataset:
digital online consultations - effects on antibiotic prescribing and health care utilization in primary care

Conditions: Sore Throat; Dysuria; Cough; Common Cold; Influenza

Summary: background/significance: with developments in mobile health and the abundance of smartphones, online consultations have emerged as a popular form of primary care in sweden. controversy exists regarding diagnostic accuracy, appropriate prescription of antibiotics, and effects on care-seeking patient behavior following implementation of online consultations. as empirical research is lacking, the investigators seek to evaluate online primary care consultations compared to physical consultations with regards to non-inferiority of antibiotic prescription for chief complaint of sore throat. methods: medical record data is used to identify patients with a chief complaint of sore throat, cough/common cold/influenza, or dysuria after choosing online (digi) or physical (physi) consultations. a cohort of patients with similar chief complaints prior to implementation of online consultations was used as a control group (control). prospective data from local registries and medical records was gathered 14 days the consultation. the primary outcome was rate of antibiotic prescription after sore throat. secondary outcomes included patient revisits (including hospital admissions), patient satisfaction, time to physician contact, registered diagnosis, and documentation or centor criteria and urinary tract infection (uti)-criteria. significance: results will shed light on whether antibiotic prescription differs significantly between digital and physical primary care consultations. hypotheses may also be generated as to how patients seek care in light of improved availability in a tax-sponsored healthcare system.

due to limited recruitment of physi and control patients, these cohorts will be combined into a single physical cohort to provide adequate power for analysis as per predefined required sample size.

Eligibility criteria:
inclusion criteria: * patient seeking care at primary healthcare provider (capio in skåne or capio go) * patient who according to medical record presents with sore throat, cough/common cold/influenza, or dysuria exclusion criteria: * patient who according to medical record presents with main symptom other than sore throat, cough/common cold/influenza, or dysuria. * patient under the age of 18.

Keywords: telemedicine remote consultation mobile health telehealth mhealth evisits econsultation ehealth
investigation of non-ce marked intermittent catheters for females

Conditions: Retention, Urinary

Summary: investigation of novel non-ce marked intermittent catheters. the study was a randomized, single blinded, cross-over investigation comparing two new catheters for females with a comparator catheter.

the cp324 study investigated a novel non-ce marked intermittent catheter, designed in two different variants, variant 1 and variant 2, respectively, and was conducted in denmark. the study was a randomized, single blinded, cross-over investigation comparing the two new variant catheters with a comparator catheter in 15 female ic users. for each participant, the study thus contained three test visits/treatment arms (comparator, variant 1 and variant 2, respectively), to which the 15 participants were randomized using a randomization sequence of six (i.e., there were six different random options for the order in which the participants tested the three catheters). there were 4-14 days between the test visits.

Eligibility criteria:
inclusion criteria: * female * minimum 18 years of age and with full legal capacity * daily intermittent catheterization for bladder management, with at least two catheters used on average pr. day, during the last 3 months * ability to self-catheterize * written informed consent, signed letter of authority and signed secrecy agreement given exclusion criteria: * breastfeeding * pregnancy (based on pregnancy test - urine) * participation in any other clinical study during this investigation * symptoms of urinary tract infection as judged by the investigator * any know allergies towards ingredients in the products * relevant medical history that would prevent the subject from participation (investigators judgement)
home-based early intensive hemiparesis therapy: engaging nurture

Conditions: Cerebral Palsy; Perinatal Stroke

Summary: the purpose of the study is to assess implementation and effectiveness of a caregiver-delivered rehabilitation intervention for infants and toddlers with cerebral palsy.


Eligibility criteria:
inclusion criteria: * aged three to 24 months (corrected, if premature) * clinician-identified hand asymmetry * suspected/confirmed cerebral palsy (hemiplegia or triplegia) * willing to withhold other formal upper-limb focussed treatment during the study intervention - willing to commit to completing 18 weeks of daily home-practice and attending weekly therapy sessions. exclusion criteria: * participation in formal constraint induced movement therapy (cimt) within last six months * upper limb botulinum toxin a injections within previous six months * brachial plexus injury * lower motor neuron dysfunction * upper limb congenital limb difference.
a pilot study on fertility conservative treatment of atypical endometrial hyperplasia in singapore

Conditions: Endometrial Hyperplasia; Fertility Issues; Disease Regression; Treatment Side Effects

Summary: the investigators' objective is to determine the regression rate, side effects and acceptability of mirena compared to megace in the treatment of atypical endometrial hyperplasia among women desiring fertility.

atypical endometrial hyperplasia is a growing clinical problem that increases the risk of carcinogenesis and negatively impacts fertility. although oral medical treatment may lead to regression in up to 90% of patients, they are associated with adverse side effects such as weight gain, that negatively affects fertility. to-date, there has been no rcts evaluating the performance of the mirena intrauterine system (ius) with megestrol acetate (megace) (the most effective and commonly used progestogen) in treating women with atypical hyperplasia who still desire fertility.

Eligibility criteria:
inclusion criteria: * all women diagnosed with atypical hyperplasia aged 21 years to 40 years * keen for fertility-preserving treatment exclusion criteria: * patients who are currently undergoing treatment for atypical hyperplasia * patients with a history of endometrial carcinoma

Keywords: endometrial hyperplasia fertility disease regression randomised clinical trial mirena ius megace
dpp-iv inhibitors underlying mechanism of cancer in diabetic patients

Conditions: Type 2 Diabetes Mellitus

Summary: recently, dpp-iv inhibitors are used as a novel way to augment the incretin system and one of the newest classes of medications in the treatment of type 2 diabetes mellitus (t2dm). since the dpp-iv inhibitor was first used, about 5 years have passed in usa. however, there were no major side effects including occurrence of cancers. the main mechanism for dpp-iv inhibitors is due to suppress the function of dpp-iv activity. as it is known that the suppressed dpp-iv activity is a marker for early diagnosis of cancers, the reason of disassociation is not clear. activation of receptor for advanced glycation endproduct (age) is related to sideration of cancers. meanwhile, the dpp-iv inhibitors may be related to inhibit the activation of receptor for age (rage). therefore, dpp-iv inhibitors may work as a cancer protective agent in diabetes by blocking the age-rage axis. however, it is not demonstrated why dpp-iv inhibitors have no side effect of occurrence of cancer via blocking the activation of age-rage. the investigators examined effect of dpp-iv inhibitors on frequency of cancers and the underlying mechanism using age and rage before and 5 years after administration of dpp-iv inhibitors in japanese patients with t2dm.

the age and rage are measured using elisa method in the laboratory of department of pathophysiology and therapeutics of diabetes vascular complications, kurume university, school of medicine, japan before and for 5 years after administration of dpp-iv inhibitors.

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus patients with or without cancer * patients who have no treatment with dpp-iv inhibitors. * outpatients regularly visiting hospital * patients 20 years old (gender is disregarded) exclusion criteria: * patients with a serious complication in the heart, liver or kidney * pregnant or possibly pregnant patients, or lactating patients * patients participating in other clinical study. * other than the above, patients judged inappropriate as the subjects of this study by the investigator
non-invasive brain mapping of movement facilitation in parkinson's disease

Conditions: Parkinson Disease

Summary: several strategies or contexts help patients with parkinson's disease to move more quickly or normally, however the brain mechanisms underlying these phenomena are poorly understood. the proposed studies use complimentary brain mapping techniques to understand the brain mechanisms supporting improved movements elicited by external cues. the central hypothesis is that distinct networks are involved in movement improvement depending on characteristics of the facilitating stimulus. participants will perform movement tasks during recording of brain activity with eeg and mri. the identified biomarkers may provide targets for future neuromodulation therapies to improve symptoms that are refractory to current treatments, such as freezing of gait.

the studies proposed here test the overarching hypothesis that different types of cues (visual targets, rhythmic auditory stimuli and reward incentives) facilitate movement through distinct neuroanatomic circuits and electrophysiological mechanisms, by leveraging known variability in behavioral cueing benefits across patients. aim 1 is to demonstrate behavioral dissociations between different forms of movement facilitation within patients and relate variability in cueing benefits to integrity of dissociable neuroanatomic circuits as measured by resting state and diffusion tensor magnetic resonance imaging (mri). aim 2 is to characterize the electrophysiological correlates of behavioral benefits for the different cue types using electroencephalography (eeg). patients will perform two computer tasks involving reaching and tapping movements during video recording of movements and electrophysiological recording of brain signals. experimental manipulations involve different computer stimuli that manipulate the presence or absence of sensory and motivational movement cues. the same experimental manipulations are delivered to all individual subjects. 60 patients with parkinson's disease and 30 healthy controls will perform the task during recording of brain waves from the scalp (eeg) and return for a second session to record brain activity with mri. each of the total of 2 sessions will last about 1.5 hours. patients may be asked to delay taking their morning parkinson's disease medications and perform clinical rating scales and questionnaires and undergo a movement disorders neurological exam.

Eligibility criteria:
inclusion criteria: * diagnosis of parkinson's disease based on presence of at least 2 cardinal features (tremor, rigidity or bradykinesia) or healthy adult with no neurologic disease * age \> 18 years old exclusion criteria: * dementia as indicated by score on montreal cognitive assessment \< 19 * active hallucinations or psychosis * contraindications to mri (metal implant, claustrophobia)

Keywords: movement external cueing brain mapping
evaluation of the efficiency of touch massage on the quality of life at work of nursing staff working in a cancer center. (pause "toucher massage (tm)")

Conditions: Quality of Life at Work; Paramedical Professionals; Touch Massage; Cancer Center

Summary: the goal of this clinical trial is to scientifically confirming the common perception that touch-massage (tm) breaks have a beneficial effect on the daily life of paramedics, both psychologically and physically. the main question\[s\] it aims to answer \[is/are\]: * evaluating the efficacy of tm on burnout * evaluating the efficacy of tm on anxiety * evaluating the efficacy of tm on affect * evaluating the efficacy of tm on musculoskeletal disorders researchers will compare 2 groups : control group of paramedics who do not have the benefit of tm breaks and an experimental group of paramedics taking tm break. participants in the experimental group received one 15-minute tm session per week for 6 weeks and burnout, anxiety, affect, and musculoskeletal disorders (msds) will be assessed in participants using questionnaires at different times of the study. participants in the control group complete only the same questionnaires at the same times as the experimental group. participants in the 2 arms are reviewed at 3 and 6 months to complete the questionnaires.


Eligibility criteria:
inclusion criteria: * nurses or nursing assistant working in the institut de cancérologie de l'ouest's (ico) medical oncology, surgical oncology, day clinic or early phase unit. * employees who have worked at the ico for at least 9 months. exclusion criteria: * employees who have had more than one touch/massage session at the ico in the last 6 months. * pregnant for more than 4 months (declarative) * employees who have undergone osteo-articular surgery within the last 3 months. * employees with a pre-inclusion mbi score indicating high burnout (emotional exhaustion score \>30 and depersonalisation score \>12 and personal accomplishment score \<33).

Keywords: burnout stress anxiety affect musculoskeletal disorders well-being
mechanical thrombectomy of acute ischemic stroke anterior circulation distal vessel occlusion

Conditions: Acute Ischemic Stroke

Summary: ischemic stroke continues to be of the leading causes of disability and death. distal vessel occlusion one of most presenting and disabling varieties of ischemic stroke. distal vessel occlusion stroke is a type of ischemic stroke that affects the small arteries in the brain, usually beyond the m2 segment of the middle cerebral artery. these strokes can cause various neurological symptoms depending on the location and size of the occluded vessel and the extent of the brain tissue damage

dmvos are defined by the distal thrombectomy summit group consensus statement as thromboembolic occlusion of the anterior cerebral artery, m2-m4 middle cerebral artery (mca), posterior cerebral artery (pca), posterior inferior cerebellar artery, anterior inferior cerebellar artery or superior cerebellar artery. it is estimated that 25-40% of all ais is due to dmvo.though distal vessel occlusion associated with poor disabling comorbidities'.with different aetiology weather primary embolic from (heart, carotid or aorta),thrombotic (atherosclerotic, hypertension or diabetes ,smoking \&hyperlipidaemia) or secondary distal vessel occlusion that occurs as a complication of a proximal large vessel occlusion, either spontaneously or after treatment with intravenous thrombolysis or endovascular thrombectomy. this can be due to thrombus fragmentation and migration or incomplete reperfusion of the affected vascular territory . endovascular thrombectomy is well established as a highly effective treatment for acute ischemic stroke (ais) due to proximal, large vessel occlusions (plvos). recent advances in stent retriever and aspiration catheter technology are more promising results to reach more distal vessels, with a good outcome. however, mt in m2 emerging with different technique using stent retriever or aspiration or both nowadays, evidence of other mt in distal vessel occlusion is poor.

Eligibility criteria:
inclusion criteria: * a. inclusion criteria: 1. diagnosis of an acute ischemic stroke due to an occlusion of the anterior cerebral artery (aca) in the a1-a3 segment 2. diagnosis of an acute ischemic stroke due to an occlusion of the middle cerebral artery in the distal m2 segment or the m3 segment. exclusion criteria: 1. posterior circulation small vessel occlusion 2. tandem lesions with occlusion of the ipsilateral ica were excluded.
use of an spf30 sunscreen and an after-sun-lotion in skin cancer risk patients

Conditions: Skin Cancer; Xeroderma Pigmentosum; Basal Cell Nevus Syndrome

Summary: study aim: to determine the effect of an intensified daily photoprotection over 24 months with an spf30 sunscreen and an after sun-lotion both containing liposomal dna repair enzymes in a population of patients at high-risk for skin cancer, including xeroderma pigmentosum (xp) and basal cell nevus syndrome.

an spf 30 sunscreen and a proprietary after sun lotion both containing a combination of plankton extract and micrococcus lysate (kindly provided by ateia ag, vaduz, liechtenstein) was used in a pilot study of intensified photoprotection in patients with multiple skin cancers. thirteen patients (8 women and 5 men), between 37 and 81 years old, who had had a history of multiple skin cancers were enrolled in the study. five of the patients had xeroderma pigmentosum (xp) (complementation group: a, 2; c,1; and non-classified 2); one patient xp variant, 3 patients basal cell nevus syndrome, and four patients no skin cancer syndrome. patients were instructed to apply their sunscreen regularly before sun exposure and 4.5 ml of the after sun lotion to their face and arms daily, as close to mid-day as possible for a period of up to 24 months. the patients were examined in 3-month intervals and the new appearance of actinic keratoses and skin cancers was recorded. new lesions were removed at these visits and the pathology was confirmed by histological examination, except in the cases of (multiple) actinic keratoses, whenever patients agreed. the number of skin tumors during the 24 months of the study was compared to the number in the preceding 24 month-period before study entry. the data were obtained from patient charts and/or electronic files. there was a statistical trend for less bccs during the study period compared to the prestudy period. in addition, the patients received at each of the 3-month visits a questionnaire and were asked to rate the status of their skin on face and arms during the last 3 months for various parameters on a scale from -2 (maximum worsening) to +2 (maximum improvement). the patients' ratings revealed a statistically significant improvement for several parameters: smoothness, color spots, wrinkles, burning, irritation, teleangiectasia, infections, warts, and skin lesions or sores, starting as early than at the first 3-month visit with a maximum effect seen at 12 months. no adverse effects were noted during the study.

Eligibility criteria:
inclusion criteria: * xeroderma pigmentosum * basal cell nevus syndrome * other patient with a history of multiple skin cancers (three or more lesions, including actinic keratosis, squamous cell carcinoma, basal cell carcinoma, and/or malignant melanoma) exclusion criteria: * intolerance of study preparation * allergy against study preparation * non-acceptable side effects

Keywords: photoprotection sunscreen after-sun-lotion dna repair enzymes liposomes skin cancer xeroderma pigmentosum basal cell nevus syndrome
different amounts of moxibustion in the treatment of dpn: a clinical rct study

Conditions: Diabetic Peripheral Neuropathy; Pain; Moxibustion; Randomized Controlled Trial

Summary: this study aims to provide moxibustion treatment for diabetic peripheral neuropathy (dpn) and a reference for clinical treatment of dpn moxibustion. patients will be randomly assigned to 3 clinical centers, 30 in each center, and then equally divided into 3 groups, including a drug treatment group, a 15-minute moxibustion group, and a 30-minute moxibustion group. patients in the drug treatment group were given mecobalamin tablets and epalrestat at the same time of daily treatment (hypertension and hyperlipidemia combined with basic drug treatment) for 4 weeks. the frequency of moxibustion was 15/30 minutes per acupoint twice a week for 4 weeks. the results were evaluated during the baseline period (the day before the grouping), the treatment period (the end of the 8th treatment), and the follow-up period (a month after the end of treatment). the results of this part are expected to confirm the therapeutic effect of moxibustion on diabetic peripheral neuropathy. the results of this part will be expected to confirm the optimal amount of moxibustion in the treatment of diabetic peripheral neuralgia and provide a reference for the standardization of clinical treatment of moxibustion.


Eligibility criteria:
inclusion criteria: 1. history of diabetes mellitus; 2. persistent pain and/or abnormal sensation in the extremities (at least in both lower limbs), decreased bilateral or unilateral ankle reflexes, decreased vibratory sensation (weaker in the medial ankle than in the medial tibial condyle), and decreased nerve conduction velocity on the affected side, and tcss score \>5; 3. 18 years ≤ age ≤ 80 years; 4. gender is not limited; 5. those who have the ability of independent daily life and can cooperate to complete all the examinations; 6. those who are conscious without serious mental diseases and cognitive disorders, and those who do not have serious cardiac, cerebral, hepatic, renal and other internal diseases; 7. voluntary participation and signing of informed consent. exclusion criteria: 1. those with peripheral neuropathy, ulcers and gangrene of the limbs caused by various other reasons (e.g. hypothyroidism, alcohol, drugs, heredity, etc.), or those with a history of skin ulcers or lesions that do not heal easily; 2. women who are in preparation for pregnancy, during pregnancy or breastfeeding; 3. those with acute complications such as combined diabetic ketoacidosis, lactic acidosis, severe infections, etc.; 4. those who suffer from serious liver or kidney damage or serious cardiovascular and cerebrovascular diseases (angina pectoris, myocardial infarction, multiple cerebral infarctions, cerebral haemorrhage, etc.); 5. those who have scars or pigmentation on the skin of the testing site, which will affect the accuracy of the test; 6. those who are participating in other acupuncture or drug clinical trials.

Keywords: diabetic peripheral neuropathy pain moxibustion
follow-up study to evaluate sustained clearance rates of actinic keratoses up to one year

Conditions: Actinic Keratoses

Summary: the objective of this study was to obtain long-term sustained clearance rates for subjects previously treated with imiquimod creams in studies gw01-0702, gw01-0703, gw01-0704 and gw01-0705.

this is a phase 3 longitudinal and observational study. subjects who previously enrolled in studies gw01-0702, gw01-0703, gw01-0704, and gw01-0705 and were completely cleared of their ak lesions in the selected treatment area at the end-of-study visit will return for follow-up visits at 6 and 12 months after the eos visit or until a recurrence of aks. the nct numbers for the above mentioned studies are: nct00603798 - for studies gw01-0703 and gw01-0705 nct00605176 for studies gw01-0702 and gw01-0704

Eligibility criteria:
inclusion criteria: * are willing and able to give informed consent; * have successfully completed one of the following studies: gw01-0702, gw01- 0703, gw01-0704, or gw01-0705 and have been determined to be completely clear of ak lesions at the eos visit in the designated treatment area from the previous study * are willing to participate in the study as an outpatient, make visits to the study center for follow-up evaluation, and agree to comply with all study requirements. exclusion criteria: * none. all subjects who meet the inclusion criteria above may participate.

Keywords: actinic keratoses dermatologic disease